Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer by unknown
IDENTIFICATION OF A UNIQUE TUMOR ANTIGEN AS
REJECTION ANTIGEN BY MOLECULAR CLONING AND
GENE TRANSFER
By HANS J . STAUSS, CARTER VAN WAES, MARY ANN FINK,
BARBARA STARR, AND HANS SCHREIBER
From the Department ofPathology, University ofChicago, Chicago, Illinois 60637
The most convincing evidence for the existence of tumor-specific antigens
comes from the studies of chemically induced tumors in mice (1-3) . Immuniza-
tion with these tumors, but not with normal donor tissues, caused strong
resistance to a subsequent challenge with the same tumor but no resistance to a
challenge with any other independently induced tumor (4, 5) . Thus, these
transplantation antigens were tumor specific as well as unique, i.e ., individually
distinct for each independently isolated tumor . Unique antigens were seen even
when . the tumors were induced with the same carcinogen in the same organ
system in the same strain of mice (4, 5) . This finding of unique tumor specificity
suggested that the diversity of these tumor-specific antigens is very large .
Identifying the molecular nature of these unique tumor-specific antigens that
cause tumor rejection hasproven to be extremely difficult in the past . Serological
probes with unique tumor specificity are difficult to obtain (6, 7), and the
serologically recognized antigens may not be the target for tumor rejection (8,
9) that is primarilyT cell-mediated (10) .
Like other neoplasias, UV light-induced tumors display unique tumor-specific
transplantation antigens (11, 12), and we used such tumors for studying the
nature of these antigens for the following reasons : (a) the unique tumor-specific
rejection antigens on UV-induced tumors are stronger than those on chemically
induced tumors in that UV-induced tumors often regress after transplantation
into normal mice even without prior immunization (13) ; (b) several of the tumor-
specific rejection antigens on one such UV-induced regressor (RE) tumor, called
1591-RE, have been defined by cytolyticT cell clones (14-16); (c) Philipps et al .
(17) have generated mAbs with unique specificity for this UV-induced RE tumor
that reacted with novel MHC class I molecules on this tumor; and (d) the genes
encoding these novel class I molecules have been cloned (18), identified by
transfection (18), and their DNA sequence has been determined (19) .
In this study, we determine the relationship between the novel MHC class I
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TABLE I
1591 Cell Lines Used in This Study
* RE, regressor; PRO, progressor.
A, B, C, and D represent 1591 tumor-specific antigens that are recognized by 1591-specific CTL
clones (15, 16).
molecules encoded by the cloned genes and the rejection antigens of the 1591
tumor. We positively identify one of the novel 1591 class I genes as encoding an
antigen that causes immunological tumor rejection in normal mice. Furthermore,
we show that transfection of this novel class I gene into a 1591 progressor (PRO)
tumor variant reverts the progressive growth behavior of the variant and leads
to the rejection of the gene-transfected progressor tumor by normal mice.
Materials and Methods
Animals and Tumor Lines.
￿
We obtained C3H/HeN (MTV-) mice from the National
Cancer Institute Cancer Research Facility (Bethesda, MD). The fibrosarcoma 1591-RE
was induced by UV irradiation (20) and regresses when transplanted into normal syngeneic
C3H/HeN mice. Electrophoretic analysis of seven isoenzymes revealed that the 1591
tumor displays a pattern characteristic of the C3H strain (17). The designation and the
antigenic phenotype of the 1591 cell lines used in this study are shown in Table 1. 1591-
REI (A+B+C+D+) and 1591-RE2 (A'B'C-D-) are two cloned tissue culture cell lines of
the 1591-RE tumor (15). For convenience, 1591-RE2 is referred to as 1591-RE in this
paper. The cell lines 1591-VAR3, -VAR5, and -VAR6 are progressor variants of 1591-
RE2, selected in vitro with anti-A CTL and previously referred to as 1591-AS 1, -AS4, and
-AS5, respectively (16). 1591-VAR2, -VAR4 and -VAR8 are three of the progressor
variants seen in 5 of 100 animals that were challenged with fragments of the 1591-RE
tumor (14). 1591-VAR1 is a progressor variant that has been isolated from a UV-irradiated
animal that was challenged with 1591-RE tumor fragments; it was previously referred to
as 1591-UVS7 (21). 1591-VAR7 is a variant of 1591-RE that has been isolated after in
vitro selection with anti-B CTL (16). 1591-VAR9 is a tumor variant that was isolated
from a C3H nude mouse injected with a mixture of 1591-VAR8 cells and spleen cells
from mice immunized with sublethal doses of 1591-VAR8 (22).
Chromium-release Assay.
￿
The cytotoxicity of cloned CTL lines (15) or of uncloned
mixed lymphocyte-tumor cell cultures (14) was determined as described. The percentage
of specific lysis was calculated by the formula: specific release = [(experimental release-
spontaneous release)/(total release-spontaneous release)] x 100 . Spontaneous release was
<15% of total release.
Immunological Analyses.
￿
The properties of the antibodies CP28 and CP3F4 and the
anti-A 1591 T cell lines have been described (17, 23). The anti-MHC class I mAbs were
Designation
Growth in
normal
mice* A B
Phenotypes
C D
Previous designation
Refer-
ence
1591-RE RE + + - - 1591-RE2 15
1591-REI RE + + + + 1591-RE1 15
1591-VAR1 PRO - + - ND 1591-UVS7 21
1591-VAR2 PRO - + - ND 1591-PRO-2 14
1591-VAR3 PRO - + - + 1591-AS1 16
1591-VAR4 PRO - + - ND 1591-PRO-3 14
1591-VAR5 PRO - + - + 1591-AS4 16
1591-VAR6 PRO - + - + 1591-AS5 16
1591-VAR7 RE + - - - 1591-BSI 16
1591-VAR8 PRO - + - - 1591-PRO-4 14
1591-VAR9 PRO - - - - 1591-HM$ 22151 8
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gifts from K. Ozato (National Institute of Childhood and Human Health Development,
Bethesda, MD) and their specificities have been described (24). The FAGS IVB (Becton
Dickinson & Co., Mountain View, CA) was used to quantify the degree of MHC class I
antigen expression of tumor cells and of class I gene transfectants. Cells were incubated
with the MHC class I-specific antibodies first, and then with fluorescein-coupled goat
anti-mouse Ig antibodies. The binding ratio was determined as the amount offluorescence
after staining with both antibodies, divided by the amount of fluorescence after staining
with the second antibody alone.
DNA-mediated Gene Transfer.
￿
The isolation of the novel 1591 class I genes 149, 166,
and 216 and the transfection of these genes into mouse L cells has been described in
detail (18). In this paper, the gene-transfected L cells are referred to as L149', L166',
and L216+, respectively. 1591 progressor variants were cotransfected with the cloned
1591 class I genes and with the plasmid pZipNeo (25), which contains the gene encoding
the aminoglycoside phosphotransferase (26), by the calcium phosphate precipitation
method as described (27). The cells that aquired aminoglycoside phosphotransferase
activity were selected by their ability to grow in the presence of 500,ug/ml of the antibiotic
G418 (untransfected cells consistently died after 1 wk under those conditions). The G418-
resistant cell population was cloned by limiting dilution and the individual clones were
analyzed with the FACS IVB for class I antigen expression.
Southern Blotting.
￿
DNA was extracted from tumor cell lines grown in vitro or from
spleen cells of inbred mouse strains and was digested to completion using an excess of
restriction enzyme (New England BioLabs, Beverly, MA). The digested DNA was sepa-
rated on a 0.9% agarose gel and blotted onto zetabind membrane (AMF-Cuno, Meriden,
CT) by capillary flow using 20 X SSC as transfer buffer. The conditions of the hybridi-
zation and the origin of the MHC class I-specific probe 149.6-6 have been described (18).
Results
Loss of the Novel MHC Class I Genes from Tumor Variants that Grow Progressively
in Normal Mice. The 1591 tumor contains three novel class I genes that account
for the abnormal reactivity of the tumor cells with MHC class I-specific mAbs
(18). In addition, the 1591-RE1 tumor expresses multiple, independent, CTL-
defined antigens (15), each of which can independently cause tumor rejection.
In the first part of our study we determined whether there is a correlation
between the presence of the novel class I genes and the expression of a CTL-
defined antigen . We have previously described (16) a 1591-RE tumor cell line,
designated 1591-RE2, which expresses in addition to the novel class I antigens
only one known rejection antigen, namely the one previously defined as "A" by
cytolytic T cell clones. For convenience 1591-RE2 is referred to in this paper as
1591-RE. We used this 1591-RE tumor for analyzing the biological significance
of the novel class I gene products and to determine their possible role in tumor
rejection . 1591-RE tumor variants that had acquired progressor phenotype either
after selection in vitro with the anti-A CTL line (16) or after selection in vivo
by the normal host (14) were tested for the presence of the three novel class I
genes. Since these genes contain novel restriction enzyme sites, they are detect-
able as restriction enzyme fragment length polymorphisms in the genomic 1591-
RE DNA (18). Fig. 1 shows a Southern blot of DNA from 1591-RE and from
six progressor variants, and it shows that all the progressor variants had lost a
polymorphic band (arrow) that, as we have shown previously (18), represents the
novel 1591 class I genes 216, 166, and 149. All progressor variants display a
class I restriction fragment pattern identical to normal C3H DNA. Thus, ourSTAUSS ET AL.
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FIGURE 1 .
￿
Loss of the novel MHC class I genes 216, 166, and 149 in 1591 progressor
variants . DNA from the parental regressor tumor, 1591-RE (lane 2) and from six progressor
variants (lanes 3-8) derived from this tumor was digested with the restriction enzyme Pst I
and analyzed by Southern blotting with the class I-specific probe 149.6-6 derived from gene
149 (18). Spleen DNA from the C3H HeN MTV- strain (lane 1) is used as a control . VAR1,
VAR2, and VAR4 are progressor variants of 1591-RE derived in vivo by immune selection,
by UV-irradiated, or by normal mice (14, 21) and VAR3, VAR5, and VAR6 are progressor
variants of 1591-RE selected in vitro with anti-A CTL (16) . For details of the variants see
Table 1 . The positions of the size markers are indicated by kb numbers .
results indicate that progressively growing variants of the 1591-RE regressor
tumor always lose all three novel class I genes: 216, 166, and 149 .
The NovelMHC Class I Gene 216 Encodes the 1591 Tumor-specific Antigen Defined
by Anti-A CTL . We have shown previously (16) that tumor variants selected for
the loss of the anti-A CTL-defined antigen are no longer rejected by normal
mice, implicatinga close linkage between (or even identity of) the A antigen and
the antigen leading to tumor rejection . However, careful attempts to block A
antigen-specific CTL clones with antibodies specific for any one of the three
novel class I MHC antigens encoded by the 216, 166, or 149 genes failed (23) .
Therefore, the relationship of the serologically defined novel class I antigens to
the CTL-defined antigen remained uncertain . In the following experiments, we
used gene-transfected L cells to determine whether any of the three novel MHC
class I genes (149, 166, or 216) encoded the antigen recognized by anti-A CTL .
Because of the commonly seen instability of the expression of the introduced
genes after DNA-mediated gene transfer, we recloned the gene-transfected cell
lines. The analysis of the recloned gene transfectants with a panel of MHC class1520
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FIGURE 2 .
￿
The 1591 class I genes 216, 166, and 149 account for all the novel MHC class I
antigens that have previously been detected on 1591-REusingMHC class I-specific antibodies .
Furthermore, the novel class I gene 216 selectively encodes for the antigen reactive with the
syngeneic tumor-specific mAbCP28 (17). The FACS IVB was used to determine the indirect
fluorescence listed as binding ratio, i . e., fluorescence of thetumor cells stained with the first
andsecond antibody over the fluorescence ofthetumor cells stained with the second antibody
alone for background (for details see Materials and Methods) . The bars from left to right
indicate respectively the binding of CP28, 34-2-12 (Dd), 34-5-8 (Dd), 28-14-8 (LdDb , q), 34-4-
20 (LdDd), 30-5-7 (L dDgLqLb), 23-5-21 (DbDdD, .q .p), andCP3F4 to the parental 1591-RE tumor
or the gene-transfected L cells.
I-specific antibodies confirmed that the transfectants had the same reactivity as
described previously (18) . Fig . 2 summarizes the results of a FACS analysis of
1591 tumor cells and of gene-transfected L cells using eight distinct mAbs . The
I, cells transfected with the gene 216 react only with the CP28 antibody and not
with any of the otherMHC class I-specific antibodies . The gene 149-transfected
L cells react only with the 28-14-8 antibody, while L cells transfected with the
166 gene react with the 28-14-8, the 30-5-7, the 23-5-21, and the CP3F4
antibodies . Together, the molecules encoded by the genes 216, 166, and 149
contain all the novel class I determinants that are detectable on the 1591 tumor
(17) . The analysis of the fluorescence histograms of the recloned transfected L
cells indicated that there was no detectable level (<I%) of antigen loss variants
in the cell population (data not shown) . These gene-transfected cell lines were
then labeled with "Cr and used as targets for the 1591 tumor-specific CTL lines.
Fig . 3 shows that only the 216 gene-transfected L cell line was killed by the
anti-A CTL line, while L cells transfected with the 166 gene or the 149 gene
were not affected by the anti-A CTL clone . The A-B+C-D- or the A-B-C-D-
variants of 1591 were not killed . As expected, however, the A+B-C-D- variant
of 1591 was killed by the anti-A CTL, as was the A'B'C-D- parental 1591-RE
tumor line . Anti-B, anti-C, or anti-D CTL did not kill any of the L cells
transfected with the novel MHC class I genes (not shown) . Together, our data
clearly indicate that the 216 gene-encoded novel class I antigen is recognized by
both the CP28 mAb (Fig . 2) as well as the anti-A CTL clone (Fig . 3) .
The Cytolytic T Cell Response Against the 1591-RE Tumor Is Directed Primarily
Against the 216 Gene Product .
￿
Since the 1591-RE tumor expresses three novelSTAUSS ET AL .
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FIGURE 3 .
￿
Selective recognition of the 216 gene-encoded, CP28-recognized antigen by the
tumor-specific T cell clone anti-A . This T cell line defines the A antigen on the 1591 tumor
as rejection antigen because it selects in vitro from the parental regressor tumor for antigen-
loss variants that grow progressively in normal mice .The 1591-RE (A'B'C-D-)and the 1591-
VAR7 (A+B-C-D-) tumor cells, and the 216 gene-transfected L cells are lysed by this CTL
clone . L cells transfected with the 1591 class I genes 149 or 166, or theA- variants of the
1591 tumorVAR8 and VAR9 (see Table I), or an unrelated UV-induced C3H tumor (2240-
RE) are not lysed in a 4.5-h
51 Cr release assay .
class I antigens encoded by gene 216, 166, and 149, we next determined the
individual role of the different gene products in a syngeneic anti-tumor CTL
response . T cells from syngeneic animals that had been immunized with the
1591-RE tumor were restimulated in vitro with 1591-RE1 cells for 6 d. Fig . 4
shows the lytic activity of this uncloned T cell population . L cells transfected
with gene 216 are lysed most efficiently, while L cells transfected with gene 166
or 149 are lysed to a lesser extent . L cells transfected with the thymidine kinase
(tk)' gene alone are not lysed by these effector T cells . This suggests that the
1591-RE1 tumor induces a CTL response in the syngeneic host that is mainly
directed against the 216 gene-encoded antigen, although the antigens encoded
by the genes 149 and 166 are also recognized by these anti-1591 CTL.
Immunization with 216 Gene-transfected Cells Leads to Radioresistant A Antigen-
Specific Tumor Rejection. We next tested whetherthe 216 gene-encoded antigen
would alone be sufficient to induce radioresistant transplantation immunity to
protect against a challenge with the 1591 tumor . Syngeneic C3H mice were
immunized with 1591-VAR7 (A''B-) regressor tumor cells, L cells transfected
with gene 216 (A+B-), or L cells transfected with the tk gene only (A-B-) . After
sublethal irradiation these animals were challenged with the A'B' 1591-RE or
the A-B+ 1591-VAR8 tumor, respectively . Fig . 5 shows that immunization with
the 216 gene transfectants protected against the growth of the 1591-RE tumor
but not against growth of the 1591-VAR8 tumor that does not express the 216
gene-encoded A antigen . As expected, immunization with the 1591-VAR7
' Abbreviation used in this paper:
￿
tk, thymidine kinase .1522
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FIGURE 4.
￿
Lytic reactivity of spleen cells from 1591-RE1 (A'B'C'D')-immunized mice with
Lcellstransfected with 1591 classIgenes 216, 166, or 149. Thespleen cells were restimulated
in vitro with 1591-REI cells for6 d before they were used as effectors in a 4.5-h "Cr release
assay. The 216 gene transfectant is lysed most effectively, while L cells transfected with the
149 or the 166 class I gene are lysed to a lesser degree. L cells transfected with the tk gene
only are not lysed.
variant that shares a 1591 tumor lineage-specific antigen (designated H) with
the 1591-RE and 1591-VAR8 tumors (22), leads to transplantation resistance to
challenge with 1591-RE as well as 1591-VAR8. Immunization with L cells
transfected with the tk gene only does not prevent the growth of either the
1591-RE or the 1591-VAR8 tumor, since the C31-1-derived L cells do not express
any of the known unique tumor-specific antigens found on tumor cells of the
1591 lineage. These data indicate that 216 gene-transfected L cells can be used
to induce an A antigen-specific radioresistant immunity that prevents the out-
growth of A antigen-positive tumor cells.
Transfection of an A - 1591 Progressor Tumor with the Novel Tumor Class I Gene
216 Abolishes the Progressive Growth Behavior of this Tumor. In the previous
section, we have shown that the 216 gene-encoded molecule is the most immu-
nogenic antigen expressed on the 1591-RE tumor and that the 216 gene-
encoded antigen can induce a radioresistant immunity. However, since all the in
vivo- or in vitro-derived progressor variants of the 1591-RE tumor had lost all
three novel class I genes (216, 166, and 149) simultaneously, it was not clear if
the presence of the 216 gene would alone be sufficient to establish the regressor
phenotype. To test this, we introduced by transfection the 216 gene into a
progressively growing A- 1591 variant, designated 1591-VAR8, which had lost
all 3 novel class I genes. This progressor tumor was cotransfected with the 216
gene and the gene encoding the enzyme aminoglycoside phosphotransferase,
which confers resistance to the drug G418. The G418-resistant cell population
was cloned, and 24 of 77 clones expressed the 216 gene-encoded antigen as
determined by their reactivity with the CP28 antibody. Two 216 gene-
expressing, A antigen-positive clones, designated TR216+. l and TR216+.2, and
two negative clones, designated TR216-.3 and TR216-.4, which were G418-m
E
m
E
0
0
E
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Days After Tumor Challenge
FIGURE 5. Immunization with 216 gene-transfected L cells protects against A antigen-
positive 1591 tumors. Mice were immunized with 10" A+B-C-D' 1591-VAR7 tumor cells,
with 216 gene transfectants, or with L cellstransfected with the tk gene only. 1 mo later, the
animals received a sublethal irradiation (600 rad) and were challenged with three 1-mm'
fragmentsof 1591-RE (left) or 1591-VAR8 (right) and tumor growth was measured in weekly
intervals. Theantigeniccomposition ofthecellsused forimmunization andfortumorchallenge
is shown. A and B represent two independent 1591-specific antigens defined by CTL clones
and H represents an antigen recognized by Th cellson tumorcells of the 1591 lineage (22).
resistant but did not express the 216 gene-encoded antigen, were analyzed
further. Cells of these four clones were injected into nude mice and fragments
ofthe growing tumors were used to challenge normal animals. The use oftumor
fragments grown in nude mice ensured that the cloned transfectants could still
grow as a malignant tumor in nude mice . Table II shows that the 216
gene-expressing TR216+.1 clone grew out in only one of five animals, and that
the 216 gene-expressing TR216+.2 clone was rejected in all animals despite the
fact that the mice were challenged with a large tumor dose (>108 cells). In
contrast, the clones TR216-.3 and TR216-.4, which do not express the 216
gene-encoded antigen, grew in five of five and four of five mice, respectively,
and all these mice died ofprogressive tumor growth. The single tumor that grew
in one ofthe animals challenged with the 216 gene-expressing TR216+.1 clone
was readapted to culture and was analyzed with the FACS for the expression of
the 216 gene-encoded antigen. All cells of the reisolate were negative for the
216 antigen, indicating that the cells either lost the transfected 216 gene or that
its expression was prevented by some other mechanism (Fig. 6). This variant that
had lost 216 gene expression was injected into five normal animals and tumor
growth resulted in all the mice (Table 1I). Together, these data indicate that the
stable expression of the 216 gene-encoded antigen is sufficient to change the
phenotype of a progressor tumor so that it is rejected by the normal animal.
Furthermore, the loss of the expression ofthis 216 antigen in transfected tumor
cells allows these cells to regain the progressor phenotype characteristic of the
untransfected parental progressor tumor.1524
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TABLE 11
Reversal ofMalignant Growth in Normal Mice by Transfection ofthe Novel Class I Gene 216
* A clone of the 1591-VAR8 tumor (clone VAR8.7) was transfected with the 216 gene and the
neomycin resistance gene. The G418 drug-resistant cell population was cloned andtwo clones that
expressed the 216gene-encoded antigen andtwo clones that did not express the 216gene-encoded
antigen were used to challenge five normal mice with tumor fragments (each animal was injected
with a total of 10 tumor fragments ^-1 mm' in size) or two nude mice (with five I-mm' tumor
fragments each).
$ Expression of the 216 gene product was determined by FACS IVB analysis using the mAb CP28
that specifically recognizes this gene product and a fluoresceinated second antibody. Cell lines
designated positive for expression of the 216 gene product stained at least two times above
background (binding ratio, >2), while all cell lines designated negative for 216 gene expression
stained <1 .5-fold above background (binding ratio, <1 .5).
Number ofmice with progressively growing tumors pernumber of mice challenged. Mice receiving
the 216- clones died within ^-6 wk due to the large tumor burden . The mice that were challenged
with the 216` transfectants did not develop tumors even after 4 mo except for one mouse, which
grew out an antigen loss variant ^-2.5 wk after injection. All cell lines used in this experiment
readily formed tumors in nude mice.
'One of the mice injected with the transfected 1591-VAR8 TR216'.1 cell line developed a
progressively growing tumor that was reisolated (designated 1591-VAR8 TR216.1 Reisolate) and
reanalyzed for expression of the 216 gene by FACS IVBand for tumor incidence in normal mice.
Discussion
Many years ago, studies (4, 5) clearly showed that tumor-specific antigens that
are distinct (unique) for each individual tumor can lead to a complete immuno-
logical destruction of experimental cancers. However, the molecules eliciting
(and being the target of) these immune responses have remained completely
obscure. Our present study not only gives a first example of a molecularly
defined, unique tumor-specific rejection antigen, it also points out several im-
portant problems that can be encountered in defining these rejection antigens.
Several lines of evidence clearly indicate that the novel MHC class I gene,
designated 216, encodes an antigen that elicits 1591 tumor-specific rejection and
is the target molecule of tumor rejection: (a) The most conclusive evidence
comes from the fact that transfection of the 216 gene into progressively growing
1591 tumor variants leads to the expression of the 216 gene-encoded antigen
on the tumor and to complete rejection of all cells expressing this antigen. This
was seen even though extremely large doses (i. e., 10 1-mm' fragments having
-10H-10" tumor cells) were used, and even though the mice had not been
Cell line*
Expression
of the 216
gene
product$
Tumor incidence
Normal mice
(%)I
Nude mice
1591-VAR8 TR216'.1 + 1/5' 2/2
1591-VAR8 TR216'.2 + 0/5 2/2
Total 1/10 (10)
1591-VAR8 TR216-.3 - 5/5 2/2
1591-VAR8 TR216-.4 - 4/5 2/2
Total 9/10 (90)
1591-VAR8 TR216.1 Reisolate' - 5/5(100) ND
1591-VAR8 - 8/10(80) ND
1591-RE + 0/10(0) 2/2STAUSS ET AL.
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FIGURE 6.
￿
Loss ofexpression of the transfected 216 gene in a reisolated 1591-VAR8 tumor
that grew progressively despite transfection with the 216 gene. The 216 gene-transfected
tumors analyzed are thesame as those used forthe experiments describedin TableII. Ashows
thehistogram of the 1591-VAR8 TR216*.1 cell line andB shows the histogram of the 1591-
VAR8 TR216.1 reisolate. Cells were incubated with the mAb antibody CP28 followed by
incubation with fluorescein-coupled goat anti-mouse Ig (-) or incubated with only the goat
anti-mouse Ig (-). 10' cells were analyzed with the FAGS IVB.
immunized before they were challenged with the transfected tumor. Thus, the
strength ofthe observed transplantation resistance is the same as reported before
(11) for the parental tumor 1591-RE or other UV-induced regressor tumors; (b)
our present study clearly shows that the 216 gene-encoded antigen must be lost
before the tumor can grow progressively in a normal immunocompetent mouse.
Southern blot analysis showed that all of the in vivo- or in vitro-derived
progressor variants analysed had lost the 216 gene . In agreement with this, we
also found that the one 216 gene-transfected progressor tumor that failed to be
rejected by one of the normal mice had lost completely the expression of the
216 gene-encoded molecule when reisolated from the tumor-bearing mouse; (c)
further important evidence comes from our finding that the rejection antigen
on the 1591 tumor that is encoded by the 216 gene is identical to that recognized
by cloned 1591 A antigen-specific CTL. We had previously shown (16) that this
anti-A CTL clone defines a 1591 tumor-specific rejection antigen because this
clone selected in vitro for A- variants that acquired malignant growth behavior
in normal mice; (d) finally, we have transfected the 216 gene into a cell line not
ofthe 1591 origin and we can, thereby, show that even in this different cellular
background the 216 gene-encoded antigen can induce transplantation immunity
that is 1591 tumor-specific. The immunity is also radioresistant, as would be
expected from unique tumor-specific antigens on UV-induced tumors (11). At
present, we do not know whether the novel MHC genes 166 and 149 of the
1591-REtumoralsoencode antigens that elicit and are targets oftumor rejection.
Furthermore, the three MHC class I genes 216, 166, and 149 appear to be
distinct from the genes encoding the CTL-defined B, C, and D antigens, because
the analysis of a B'C'D' 1591 tumor variant revealed that this variant had lost
the three novel class I genes (18) that we have identified. However, the genetic
origin(s) of the B, C, and D antigen is at present unknown, and it is possible that
these antigens are encoded by other, yet unidentified 1591 class I genes or by
genes that do not belong to the MHC class I gene family.
Previous studies have failed to correlate the loss ofthe novel class I genes with
tumor progression since a variant of the 1591 tumor that had lost the genes
encoding the novel class I antigens (18) was still rejected by normal mice (16)
and, therefore, retained the regressor phenotype. This might be due to the fact
that this variant still expresses the CTL-defined B, C, and D antigens (23), some1526
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of which are highly immunogenic and can cause tumor rejection in the normal
host. Our study clearly shows that all of the progressor variants derived from
the 1591-RE tumor either by selection by the normal host in vivo or by selection
in vitro usinganti-A CTL clones have lost the gene encoding the unique tumor-
specific A antigen. As would be expected, the variants did not aquire a general
resistance to lysis by CTL since they remained susceptible to lysis by tumor-
specific CTL clones that recognize less immunogenic tumor antigens that are
still retained on the progressor variants (not shown). Furthermore, we found
that the variants expressed similar levels of normal MHC class I molecules as the
parental regressor tumor (data not shown). Thus, one mechanism by which the
1591 tumor escapes immune destruction involves loss of the gene encoding a
tumor-specific class I antigen, and this is distinctly different from another
previously described mechanism that involves loss of expression of normal MHC
class I antigens (28). The latter mechanism has recently been reported (29-32)
to account for the progressive growth behavior of certain malignant tumors,
although the nature of the tumor-specific antigens on the tumors analyzed has
not been determined.
Unique tumor-specific transplantation antigens are antigenically distinct for
independently induced tumors. These different antigens may, therefore, be
encoded either by numerous different unrelated genes or by a single gene that
underwent multiple different mutational changes. Alternatively, these antigens
might be encoded by the members of a gene family such as the Ig genes, the T
cell receptor genes, the MHC class I and class II genes, or the genes of the
multiple retroviral proviruses that are present in the murine genome. Some of
these gene families are known to contain the coding information for a large
variety of distinct molecules and could therefore account for the observed
remarkable antigenic polymorphism among tumor-specific transplantation anti-
gens. It is interesting to notice that even a single malignant cell can express
multiple unique tumor-specific antigens, as has been shown for the tumor P815
(33) or 1591-RE (15). Thus, to resolve multiple unanswered questionsconcerning
the origin of these antigens and to determine if they are encoded by a family of
related genes, it is necessary to analyze more tumors and to identify, molecularly
and genetically, more unique tumor-specific transplantation antigens.
Another important and still unresolved question regardingthe origin of unique
tumor-specific antigens is whether the genes encoding such antigens are preex-
isting in the genome or whether these genes appear as the result of somatic
mutation and as such represent the product of the mutagenic action of carcino-
gens. Previous studies (34, 35) showing unique antigenicity of each of the
independent transformants which were all derived from one single parental cell
seemed to suggest somatic carcinogen-induced mutations as a likely mechanism.
However, it was not excluded by these studies that the carcinogen treatment
activated heritably, but at random, different preexisting, previously silent genes.
Such a mechanism couldalso account fortheobserved immunogenicity of tumors
in the autochthonous host (5). Furthermore, Bailey (36) has pointed out the
problems of residual heterozygosity in inbred mouse strains, which might then
be mistaken for tumor-specific antigens on tumors. Although this possibility has
not been formally excluded it is difficult to conceive how such residual hetero-STAUSS ET AL.
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zygosity could be prevalent enough to account for the fact that up to 90% of
UV-induced tumors in a given batch of mice can be highly immunogenic
regressortumors in normal miceandexpressindividually tumor-specific antigens.
In addition, the electrophoretic isoenzyme analysis ofseveral CM-derived, UV-
induced regressor tumors revealed that all these tumors, including 1591, dis-
played an isoenzyme pattern characteristic for the C3H strain (17). Furthermore,
the fact that tumors experimentally induced with a known carcinogen appear to
be more immunogenic than "spontaneous" tumors (37) might suggest that a high
dosage ofa carcinogen more frequently leads to the expression of immunogenic
tumor-specific antigens than a low dose ofa carcinogen. The appearance ofsuch
antigens might be a consequence of the known mutagenic action of most
carcinogens, including UV (38). Such an explanation would be consistent with
the observed lower immunogenicity ofspontaneous tumors that presumably arise
as a consequence of exposure to low dose of environmental carcinogens. How-
ever, whether the genes encoding these antigens preexisted and are simply
activated, or whether they are structural genes mutated by carcinogens cannot
be decided at present.
The DNA sequence ofthe 1591 genes 216, 166, and 149 has been determined
(19) and will be compared with the sequence of the potential parent genes that
have been isolated using gene-specific DNA probes. However, even though these
studies may identify a probable mechanism by which the novel tumor-specific
class I genes arose, it will be impossible to determine whether these genes
originated as a result of a somatic or a germ line mutation . This is because
normal somatic cells from the original mouse that gave rise to the 1591 tumor
are not available. Since such important autochthonous control cells are also not
available for other tumors whose tumor-specific antigens have been carefully
analyzed in the past (39), we are generating a new bank of UV-induced tumors
in which normal control cells are concurrently isolated from each tumor-bearing
mouse. Several of these new tumors are as highly immunogenic as 1591-RE or
other tumors previously induced by UV-irradiation . The new tumors will be
very useful to compare the molecular nature of other unique tumor-specific
transplantation antigens with our present findings and to determine whether or
not such antigens are encoded by related genes. Furthermore, the analysis of
these new tumors will also allow us to clearly distinguish between somatic and
germ line mutation and to understand the possible role that these molecules
might play in the establishment ofmalignant behavior.
Summary
Tumor-specific transplantation antigens are antigens that can lead to complete
immunological destruction ofa transplanted cancer by the syngeneic host. When
such antigens are expressed on cancers induced by chemical or physical carcin-
ogens, then they are usually unique, i. e., antigenically different for each
independently induced tumor. In this study, we show that the product ofa gene
encoding a novel MHC class I molecule and isolated from the murine UV light-
induced regressor tumor 1591 represents one such unique tumor-specific trans-
plantation antigen that causes tumor rejection. The major evidence comes from
our finding that 1591 progressor variants regularly lost the gene encoding this152 8
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antigen that is expressed in the parental tumor that regresses in normal mice;
furthermore, reintroduction of this gene into a 1591 progressor variant by DNA
transfection caused the progressor variant to regress in normal immunocompe-
tent mice. Thus, the progressor tumor reverted to the parental regressor phe-
notype following transfection. Consistent with the conclusion that the expression
of the novel MHC class I gene following transfection was responsible for the
regressor phenotype is also our finding that a variant of the transfected tumor
that had lost expression of the transfected gene resumed its progressive growth
behavior. Finally, we show that the molecule encoded by the novel class I gene
is specifically recognized by a syngeneic tumor-specific cytolytic T cell clone that
we have previously shown to select in vitro for progressor variants from the
parental regressor tumor cell line. It remains to be determined to what extent
unique tumor-specific rejection antigens of other highly immunogenic regressor
tumors are encoded by novel MHC class I genes and whether these genes
represent germline mutations or somatic mutations caused by the carcinogen
treatment.
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